STRO Nov 2024 2.500 put
| Previous close | 0.4000 |
| Open | 0.4000 |
| Bid | 0.1500 |
| Ask | 0.3000 |
| Strike | 2.50 |
| Expiry date | 2024-11-15 |
| Day's range | 0.4000 - 0.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 16 |
Simply Wall St.Shareholders Will Likely Find Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Compensation Acceptable
Key Insights Sutro Biopharma to hold its Annual General Meeting on 6th of June Total pay for CEO Bill Newell includes...
GlobeNewswireSutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 - - Patient expansion phase well underway in Phase 2 study of luvelta in combination with bevacizumab; enrollment is expected to complete in the first half of 2024 - - The randomized portion of REFRαME-O1, the registration-enabling study of luvelta for patients with platinum-resistant ovarian cancer, is
ZacksAnalysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for
Sutro Biopharma (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
